Phase I Study of ICP-332 in Healthy Subjects

Description

A multiple ascending dose phase I study of ICP-332 in healthy subjects

Conditions

Healthy Subjects

Talk to us

Study Overview

On this page

Study Details

Study overview

A multiple ascending dose phase I study of ICP-332 in healthy subjects

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-332 in Healthy Subjects

Phase I Study of ICP-332 in Healthy Subjects

Condition
Healthy Subjects
Intervention / Treatment

-

Contacts and Locations

Baltimore

Pharmaron CPC Inc., Baltimore, Maryland, United States, 21201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Voluntarily sign the informed consent form
  • 2. Body mass index (BMI) of ≥ 18.5 kg/m2 and \< 30 kg/m2
  • 3. Male or infertile female subjects who are between 18-55 years old (inclusive)
  • 1. Significant current or past acute or chronic disease or condition.
  • 2. A history of tuberculosis or current active/latent infection.
  • 3. With a history of drug or food allergy, or allergy to any of the composition components of the study drug, or allergic disease.
  • 4. Subjects with clinically significant abnormalities in the screening examinations.

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

InnoCare Pharma Inc.,

Study Record Dates

2024-12-25